China hits pharma company with major fine
China’s competition watchdog has fined a major pharmaceutical group about €97.6 million for fixing the resale price of multiple drugs over a four year period.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.